About this trial
Small vessel disease (SVD) is a major cause of stroke and contributor to dementia cases. As work continues to develop new treatments to address the impact of SVD, new imaging techniques are needed to identify and track the progression of brain changes that occur with SVD. Magnetic Resonance Imaging (MRI) is the gold standard to diagnose poor brain health due to small vessel disease. However, current MRI systems are expensive and complex to operate, and so access is limited.
Low-field MRI technology, operating at magnetic field strengths many times lower than conventional MRI, can make brain imaging much more cost-effective and accessible. However, further work is needed to develop low-field MRI towards clinically feasible assessments of brain health. The University of Aberdeen hosts a unique network of researchers and imaging technologies that is now making it possible to test and develop different low-field MRI approaches towards solving key healthcare challenges.
The aim of this study is to evaluate the potential of two distinct approaches, field-cycling imaging (FCI) and ultra-low field MRI (ULF-MRI), to detect brain changes linked with small vessel disease. Automated methods will be developed to analyse images and extract measurements that detect and track progression of disease severity.
Eligibility criteria
Qualifiers
Adults ≥ 50 years old.
Subjects who do not report problems with memory.
Small vessel disease (Fazekas score 1 to 3).
Suitable body habitus.
Disqualifiers
History of major stroke (minor stroke/Transient Ischaemic Attacks or lacunar stroke are acceptable).
Individuals unable to give informed consent.
Contra-indications to MRI scanning such as implantable cardiac devices.
Trial design
Treatments tested in this trial
- Enrolment 3T MRI research scan
- Enrolment Field-cycling Imaging research scan
- Enrolment ultra-low field MRI research scan
- Follow up 3T MRI research scan
- Follow up Field-cycling Imaging research scan
- Follow up ultra-low field MRI research scan
- Enrolment cognitive assessment interview
- Follow up cognitive assessment interview
Treatment groups
Sponsors and collaborators
University of Aberdeen
Lead sponsor
NHS Grampian
Collaborator